Ashish Kabra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ashish Kabra has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Anupam Jain
Molecular and Structural Biology Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
4 shared publications- Rahul Yadav
Physical Science Department, University of Arkansas-Fort Smith, Fort Smith, AR 72904, USA; Department of Chemistry, Mississippi State University, Mississippi State, MS 39762, USA
4 shared publications - Sarita Tripathi
Molecular and Structural Biology Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
4 shared publications - Ying Li
Department of Chemistry, University of Louisville, 2320 South Brook Street, Louisville, Kentucky 40208, United States
4 shared publications - Ashish Arora
Biochemistry and Structural Biology Division, CSIR-Central Drug Research Institute, Lucknow 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
3 shared publications - John Hackett Bushweller
Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22903
3 shared publications
Latest Publications
- Open Access
- 20 April 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (2) , 35
Decoding Deubiquitinases: Roles, Mechanisms, and Therapeutic Implications
Deubiquitinases, or DUBs, have emerged as pivotal regulators of cellular homeostasis, coordinating the delicate balance between protein ubiquitination and deubiquitination. Their versatile roles span from controlling protein turnover to modulating signal transduction pathways, thereby influencing diverse cellular processes, including DNA damage repair, apoptosis, and immune responses. This review comprehensively explores the current understanding of DUBs, elucidating their structural diversity, catalytic mechanisms, physiological functions, and implications in human diseases. Moreover, we discuss the therapeutic potential of targeting DUBs in various pathological conditions, highlighting recent advancements and challenges in developing DUB-specific inhibitors.
- 20 April 2026
- Published by MDPI AG in Biophysica
- Vol. 6 (2) , 35
Open AccessDecoding Deubiquitinases: Roles, Mechanisms, and Therapeutic Implications
Deubiquitinases, or DUBs, have emerged as pivotal regulators of cellular homeostasis, coordinating the delicate balance between protein ubiquitination and deubiquitination. Their versatile roles span from controlling protein turnover to modulating signal transduction pathways, thereby influencing diverse cellular processes, including DNA damage repair, apoptosis, and immune responses. This review comprehensively explores the current understanding of DUBs, elucidating their structural diversity, catalytic mechanisms, physiological functions, and implications in human diseases. Moreover, we discuss the therapeutic potential of targeting DUBs in various pathological conditions, highlighting recent advancements and challenges in developing DUB-specific inhibitors.
- Open Access
- 3 March 2026
- Published by MDPI AG in Preprints.org
Decoding Deubiquitinases: Roles, Mechanisms, and Therapeutic Implications
Deubiquitinases or DUBs have emerged as pivotal regulators in cellular homeostasis, coordinating the delicate balance of protein ubiquitination and deubiquitination. Their versatile roles span from controlling protein turnover to modulating signal transduction pathways, thereby influencing diverse cellular processes such as DNA damage repair, apoptosis, and immune responses. This review comprehensively explores the current understanding of DUBs, elucidating their structural diversity, catalytic mechanisms, physiological functions, and implications in human diseases. Moreover, we discuss the therapeutic potential of targeting DUBs in various pathological conditions, highlighting recent advancements and challenges in developing DUB-specific inhibitors.
- 3 March 2026
- Published by MDPI AG in Preprints.org
Open AccessDecoding Deubiquitinases: Roles, Mechanisms, and Therapeutic Implications
Deubiquitinases or DUBs have emerged as pivotal regulators in cellular homeostasis, coordinating the delicate balance of protein ubiquitination and deubiquitination. Their versatile roles span from controlling protein turnover to modulating signal transduction pathways, thereby influencing diverse cellular processes such as DNA damage repair, apoptosis, and immune responses. This review comprehensively explores the current understanding of DUBs, elucidating their structural diversity, catalytic mechanisms, physiological functions, and implications in human diseases. Moreover, we discuss the therapeutic potential of targeting DUBs in various pathological conditions, highlighting recent advancements and challenges in developing DUB-specific inhibitors.
- Open Access
- 7 June 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (6) , 668
Unveiling the Druggable Landscape of Bacterial Peptidyl tRNA Hydrolase: Insights into Structure, Function, and Therapeutic Potential
Bacterial peptidyl tRNA hydrolase (Pth) or Pth1 emerges as a pivotal enzyme involved in the maintenance of cellular homeostasis by catalyzing the release of peptidyl moieties from peptidyl-tRNA molecules and the maintenance of a free pool of specific tRNAs. This enzyme is vital for bacterial cells and an emerging drug target for various bacterial infections. Understanding the enzymatic mechanisms and structural intricacies of bacterial Pth is pivotal in designing novel therapeutics to combat antibiotic resistance. This review provides a comprehensive analysis of the multifaceted roles of Pth in bacterial physiology, shedding light on its significance as a potential drug target. This article delves into the diverse functions of Pth, encompassing its involvement in ribosome rescue, the maintenance of a free tRNA pool in bacterial systems, the regulation of translation fidelity, and stress response pathways within bacterial systems. Moreover, it also explores the druggability of bacterial Pth, emphasizing its promise as a target for antibacterial agents and highlighting the challenges associated with developing specific inhibitors against this enzyme. Structural elucidation represents a cornerstone in unraveling the catalytic mechanisms and substrate recognition of Pth. This review encapsulates the current structural insights of Pth garnered through various biophysical techniques, such as X-ray crystallography and NMR spectroscopy, providing a detailed understanding of the enzyme’s architecture and conformational dynamics. Additionally, biophysical aspects, including its interaction with ligands, inhibitors, and substrates, are discussed, elucidating the molecular basis of bacterial Pth’s function and its potential use in drug design strategies. Through this review article, we aim to put together all the available information on bacterial Pth and emphasize its potential in advancing innovative therapeutic interventions and combating bacterial infections.
- 7 June 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (6) , 668
Open AccessUnveiling the Druggable Landscape of Bacterial Peptidyl tRNA Hydrolase: Insights into Structure, Function, and Therapeutic Potential
Bacterial peptidyl tRNA hydrolase (Pth) or Pth1 emerges as a pivotal enzyme involved in the maintenance of cellular homeostasis by catalyzing the release of peptidyl moieties from peptidyl-tRNA molecules and the maintenance of a free pool of specific tRNAs. This enzyme is vital for bacterial cells and an emerging drug target for various bacterial infections. Understanding the enzymatic mechanisms and structural intricacies of bacterial Pth is pivotal in designing novel therapeutics to combat antibiotic resistance. This review provides a comprehensive analysis of the multifaceted roles of Pth in bacterial physiology, shedding light on its significance as a potential drug target. This article delves into the diverse functions of Pth, encompassing its involvement in ribosome rescue, the maintenance of a free tRNA pool in bacterial systems, the regulation of translation fidelity, and stress response pathways within bacterial systems. Moreover, it also explores the druggability of bacterial Pth, emphasizing its promise as a target for antibacterial agents and highlighting the challenges associated with developing specific inhibitors against this enzyme. Structural elucidation represents a cornerstone in unraveling the catalytic mechanisms and substrate recognition of Pth. This review encapsulates the current structural insights of Pth garnered through various biophysical techniques, such as X-ray crystallography and NMR spectroscopy, providing a detailed understanding of the enzyme’s architecture and conformational dynamics. Additionally, biophysical aspects, including its interaction with ligands, inhibitors, and substrates, are discussed, elucidating the molecular basis of bacterial Pth’s function and its potential use in drug design strategies. Through this review article, we aim to put together all the available information on bacterial Pth and emphasize its potential in advancing innovative therapeutic interventions and combating bacterial infections.
- 7 July 2022
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 13 (8) , 1363-1369
Small-Molecule Inhibitors of the MLL1 CXXC Domain, an Epigenetic Reader of DNA Methylation
The CXXC domain is a reader of DNA methylation which preferentially binds to unmethylated CpG DNA motifs. Chromosomal translocations involving the MLL1 gene produce in frame fusion proteins in which the N-terminal portion of the MLL1 protein harboring its CXXC domain is fused to the C terminal portion of multiple partners. For the MLL-AF9 fusion, mutations which disrupt CXXC domain-DNA binding abrogate the ability to cause leukemia in mice. Based on this, we initiated an effort to develop small-molecule inhibitors of the MLL1 CXXC domain as a novel approach to therapy. We developed a fluorescence polarization-based assay for MLL CXXC domain-DNA binding and screened a library of Cys-reactive molecules. For the most potent hit from this screen, we have synthesized a library of analogs to explore the structure-activity relationship, defined the binding site using chemical shift perturbations in NMR spectra, and explored the selectivity of compounds across the CXXC domain family.
- 7 July 2022
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 13 (8) , 1363-1369
Small-Molecule Inhibitors of the MLL1 CXXC Domain, an Epigenetic Reader of DNA Methylation
The CXXC domain is a reader of DNA methylation which preferentially binds to unmethylated CpG DNA motifs. Chromosomal translocations involving the MLL1 gene produce in frame fusion proteins in which the N-terminal portion of the MLL1 protein harboring its CXXC domain is fused to the C terminal portion of multiple partners. For the MLL-AF9 fusion, mutations which disrupt CXXC domain-DNA binding abrogate the ability to cause leukemia in mice. Based on this, we initiated an effort to develop small-molecule inhibitors of the MLL1 CXXC domain as a novel approach to therapy. We developed a fluorescence polarization-based assay for MLL CXXC domain-DNA binding and screened a library of Cys-reactive molecules. For the most potent hit from this screen, we have synthesized a library of analogs to explore the structure-activity relationship, defined the binding site using chemical shift perturbations in NMR spectra, and explored the selectivity of compounds across the CXXC domain family.
- Open Access
- 8 March 2022
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 7 (11) , 9936-9943
Observation of Arginine Side-Chain Motions Coupled to the Global Conformational Exchange Process in Deubiquitinase A
Coupled motions have been demonstrated to be functionally important in a number of enzymes. Noncovalent side-chain interactions play essential roles in coordinating the motions across different structural elements in a protein. However, most of the dynamic studies of proteins are focused on backbone amides or methyl groups in the side chains and little is known about the polar and charged side chains. We have previously characterized the conformational dynamics of deubiquitinase A (DUBA), an isopeptidase, on the microsecond-to-millisecond (μs–ms) time scales with the amide 1H Carr–Purcell–Meiboom–Gill (CPMG) experiment. We detected a global conformational exchange process on a time scale of approximately 200 μs, which involves most of the structural elements in DUBA, including the active site and the substrate binding interface. Here, we extend our previous study on backbone amides to the arginine side-chain Nε–Hε groups using a modified 1H CPMG pulse sequence that can efficiently detect both backbone amide and arginine side-chain Nε–Hε signals in a single experiment. We found that the side chains of three arginines display motions on the same time scale as the backbone amides. Mutations of two of the three arginines to alanines result in a decrease in enzyme activity. One of these two arginines is located in a loop involved in substrate binding. This loop is not visible in the backbone amide-detected experiments due to excess line broadening induced by motions on the μs–ms time scales. These results clearly demonstrate that the motions of some arginine side chains are coupled to the global conformational exchange process and provide an additional probe for motions in a functionally important loop that did not yield visible backbone amide signals, suggesting the value of side-chain experiments on DUBA. The modified 1H CPMG pulse sequence allows the simultaneous characterization of backbone and arginine side-chain dynamics without any increase in data acquisition time and can be applied to the dynamic studies of any protein that displays measurable amide 1H relaxation dispersion.
- 8 March 2022
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 7 (11) , 9936-9943
Open AccessObservation of Arginine Side-Chain Motions Coupled to the Global Conformational Exchange Process in Deubiquitinase A
Coupled motions have been demonstrated to be functionally important in a number of enzymes. Noncovalent side-chain interactions play essential roles in coordinating the motions across different structural elements in a protein. However, most of the dynamic studies of proteins are focused on backbone amides or methyl groups in the side chains and little is known about the polar and charged side chains. We have previously characterized the conformational dynamics of deubiquitinase A (DUBA), an isopeptidase, on the microsecond-to-millisecond (μs–ms) time scales with the amide 1H Carr–Purcell–Meiboom–Gill (CPMG) experiment. We detected a global conformational exchange process on a time scale of approximately 200 μs, which involves most of the structural elements in DUBA, including the active site and the substrate binding interface. Here, we extend our previous study on backbone amides to the arginine side-chain Nε–Hε groups using a modified 1H CPMG pulse sequence that can efficiently detect both backbone amide and arginine side-chain Nε–Hε signals in a single experiment. We found that the side chains of three arginines display motions on the same time scale as the backbone amides. Mutations of two of the three arginines to alanines result in a decrease in enzyme activity. One of these two arginines is located in a loop involved in substrate binding. This loop is not visible in the backbone amide-detected experiments due to excess line broadening induced by motions on the μs–ms time scales. These results clearly demonstrate that the motions of some arginine side chains are coupled to the global conformational exchange process and provide an additional probe for motions in a functionally important loop that did not yield visible backbone amide signals, suggesting the value of side-chain experiments on DUBA. The modified 1H CPMG pulse sequence allows the simultaneous characterization of backbone and arginine side-chain dynamics without any increase in data acquisition time and can be applied to the dynamic studies of any protein that displays measurable amide 1H relaxation dispersion.
- Open Access
- 18 February 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (7) , eabl4618
KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer
EP300, a transcription coactivator important in proliferation and differentiation, is frequently mutated in diverse cancer types, including small cell lung cancer (SCLC). While these mutations are thought to result in loss of EP300 function, the impact on tumorigenesis remains largely unknown. Here, we demonstrate that EP300 mutants lacking acetyltransferase domain accelerate tumor development in mouse models of SCLC. However, unexpectedly, complete Ep300 knockout suppresses SCLC development and proliferation. Dissection of EP300 domains identified kinase inducible domain-interacting (KIX) domain, specifically its interaction with transcription factors including MYB, as the determinant of protumorigenic activity. Ala 627 in EP300 KIX results in a higher protein-binding affinity than Asp 647 at the equivalent position in CREBBP KIX, underlying the selectivity of KIX-binding partners for EP300. Blockade of KIX-mediated interactions inhibits SCLC development in mice and cell growth. This study unravels domain-specific roles for EP300 in SCLC and unique vulnerability of the EP300 KIX domain for therapeutic intervention.
- 18 February 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (7) , eabl4618
Open AccessKIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer
EP300, a transcription coactivator important in proliferation and differentiation, is frequently mutated in diverse cancer types, including small cell lung cancer (SCLC). While these mutations are thought to result in loss of EP300 function, the impact on tumorigenesis remains largely unknown. Here, we demonstrate that EP300 mutants lacking acetyltransferase domain accelerate tumor development in mouse models of SCLC. However, unexpectedly, complete Ep300 knockout suppresses SCLC development and proliferation. Dissection of EP300 domains identified kinase inducible domain-interacting (KIX) domain, specifically its interaction with transcription factors including MYB, as the determinant of protumorigenic activity. Ala 627 in EP300 KIX results in a higher protein-binding affinity than Asp 647 at the equivalent position in CREBBP KIX, underlying the selectivity of KIX-binding partners for EP300. Blockade of KIX-mediated interactions inhibits SCLC development in mice and cell growth. This study unravels domain-specific roles for EP300 in SCLC and unique vulnerability of the EP300 KIX domain for therapeutic intervention.
- 8 January 2021
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 60 (3) , 201-209
Conformational Dynamics of Deubiquitinase A and Functional Implications
Deubiquitinase A (DUBA) belongs to the ovarian tumor family of deubiquitinating enzymes and was initially identified as a negative regulator of type I interferons, whose overproduction has been linked to autoimmune diseases. The deubiquitinating activity of DUBA is positively regulated by phosphorylation at a single serine residue, S177, which results in minimal structural changes. We have previously shown that phosphorylation induces a two-state conformational equilibrium observed only in the active form of DUBA, highlighting the functional importance of DUBA dynamics. Here, we report the conformational dynamics of DUBA on the microsecond-to-millisecond time scales characterized by nuclear magnetic resonance relaxation dispersion experiments. We found that motions on these time scales are highly synchronized in the phosphorylated and nonphosphorylated DUBA. Despite the overall similarity of these two forms, different dynamic properties were observed in helix α1 and the neighboring regions, including residue S177, which likely contribute to the activation of DUBA by phosphorylation. Moreover, our data suggest that transient unfolding of helix α6 drives the global conformational process and that mutations can be introduced to modulate this process, which provides a basis for future studies to define the exact functional roles of motions in DUBA activation and substrate specificity.
- 8 January 2021
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 60 (3) , 201-209
Conformational Dynamics of Deubiquitinase A and Functional Implications
Deubiquitinase A (DUBA) belongs to the ovarian tumor family of deubiquitinating enzymes and was initially identified as a negative regulator of type I interferons, whose overproduction has been linked to autoimmune diseases. The deubiquitinating activity of DUBA is positively regulated by phosphorylation at a single serine residue, S177, which results in minimal structural changes. We have previously shown that phosphorylation induces a two-state conformational equilibrium observed only in the active form of DUBA, highlighting the functional importance of DUBA dynamics. Here, we report the conformational dynamics of DUBA on the microsecond-to-millisecond time scales characterized by nuclear magnetic resonance relaxation dispersion experiments. We found that motions on these time scales are highly synchronized in the phosphorylated and nonphosphorylated DUBA. Despite the overall similarity of these two forms, different dynamic properties were observed in helix α1 and the neighboring regions, including residue S177, which likely contribute to the activation of DUBA by phosphorylation. Moreover, our data suggest that transient unfolding of helix α6 drives the global conformational process and that mutations can be introduced to modulate this process, which provides a basis for future studies to define the exact functional roles of motions in DUBA activation and substrate specificity.
- Open Access
- 1 March 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (12) , 3945-3951
Modulation of conformational equilibrium by phosphorylation underlies the activation of deubiquitinase A
- 1 March 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (12) , 3945-3951
Open AccessModulation of conformational equilibrium by phosphorylation underlies the activation of deubiquitinase A
- 19 September 2018
- Published by Springer Nature in Biomolecular NMR Assignments
- Vol. 13 (1) , 37-42
Backbone 1H, 13C, and 15N resonance assignments of deubiquitinase A in non-phosphorylated and phosphorylated forms
Ubiquitination is one of the most prevalent forms of post-translational modifications that are important for regulating many cellular processes in eukaryotes. Deubiquitinases are proteases that hydrolyze the isopeptide or peptide bonds formed between ubiquitin and the target proteins or within a polyubiquitin chain. Deubiquitinase A (DUBA) is a deubiquitinase known to be a negative regulator of innate immune responses in humans by suppressing production of type I interferons (INF-I). Excess INF-I production has been associated with autoimmune diseases. Phosphorylation of a single serine residue at position 177 is essential for the protease activity of DUBA. The structural and mechanistic basis of DUBA activation by phosphorylation and substrate specificity is not well understood. Here, we report the backbone resonance assignments of the isoform 2 of DUBA in both non-phosphorylated and phosphorylated forms. The reported assignments form the basis for future NMR studies on the structural and dynamical properties of both active and inactive forms of DUBA.
- 19 September 2018
- Published by Springer Nature in Biomolecular NMR Assignments
- Vol. 13 (1) , 37-42
Backbone 1H, 13C, and 15N resonance assignments of deubiquitinase A in non-phosphorylated and phosphorylated forms
Ubiquitination is one of the most prevalent forms of post-translational modifications that are important for regulating many cellular processes in eukaryotes. Deubiquitinases are proteases that hydrolyze the isopeptide or peptide bonds formed between ubiquitin and the target proteins or within a polyubiquitin chain. Deubiquitinase A (DUBA) is a deubiquitinase known to be a negative regulator of innate immune responses in humans by suppressing production of type I interferons (INF-I). Excess INF-I production has been associated with autoimmune diseases. Phosphorylation of a single serine residue at position 177 is essential for the protease activity of DUBA. The structural and mechanistic basis of DUBA activation by phosphorylation and substrate specificity is not well understood. Here, we report the backbone resonance assignments of the isoform 2 of DUBA in both non-phosphorylated and phosphorylated forms. The reported assignments form the basis for future NMR studies on the structural and dynamical properties of both active and inactive forms of DUBA.